{"id":546112,"date":"2021-06-03T23:20:01","date_gmt":"2021-06-03T23:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=546112"},"modified":"2021-06-03T23:20:01","modified_gmt":"2021-06-03T23:20:01","slug":"nonmuscle-invasive-bladder-cancer-nmibc-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonmuscle-invasive-bladder-cancer-nmibc-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_546112.html","title":{"rendered":"Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Non-muscle<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cNon-muscle Invasive Bladder Cancer (NMIBC)\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Non-muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-muscle Invasive Bladder Cancer (NMIBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Non-muscle Invasive Bladder Cancer (NMIBC)-Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Non-muscle Invasive Bladder Cancer (NMIBC)–Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Non-muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-muscle Invasive Bladder Cancer (NMIBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    The total diagnosed prevalent population of NMIBC in the seven major market ranges was 533,263 in 2017, which will increase for the study period i.e., 2017–2030.<\/p>\n<\/li>\n

  2. \n

    In 2017, the diagnosed prevalent population of low-grade NMIBC patients was 136,822 and high-grade NMIBC patients were 76,962 in the US, which is anticipated to increase in the forecast period.<\/p>\n<\/li>\n

  3. \n

    In Japan, the diagnosed prevalent population of NMIBC was 74,691 in 2017.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.The Non-muscle Invasive Bladder Cancer (NMIBC) market report covers a descriptive overview and comprehensive insight of the Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology and Non-muscle Invasive Bladder Cancer (NMIBC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.The Non-muscle Invasive Bladder Cancer (NMIBC) market report provides insights into the current and emerging therapies.<\/p>\n

    3.Non-muscle Invasive Bladder Cancer (NMIBC) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4.The Non-muscle Invasive Bladder Cancer (NMIBC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-muscle Invasive Bladder Cancer (NMIBC) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/non-muscle-invasive-bladder-cancer-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Non-muscle Invasive Bladder Cancer (NMIBC): Overview<\/strong><\/p>\n

    Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. Bladder cancer is the 6th most common cancer in the United States. Nearly 84,000 people will be diagnosed in the United States with bladder cancer in 2021.<\/p>\n

    The key players involved in the Non-muscle Invasive Bladder Cancer (NMIBC) Market<\/a>:<\/strong><\/p>\n

     <\/p>\n

      \n
    1. \n

      FKD Therapies Oy\/ Ferring Pharmaceuticals<\/p>\n<\/li>\n

    2. \n

      Merck<\/p>\n<\/li>\n

    3. \n

      ViventiaBio\/Sesen Bio<\/p>\n<\/li>\n

    4. \n

      ImmunityBio\/ Altor Biosciences<\/p>\n<\/li>\n

    5. \n

      Theralase<\/p>\n<\/li>\n

    6. \n

      CG Oncology<\/p>\n<\/li>\n

    7. \n

      Seattle Genetics<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Non-muscle Invasive Bladder Cancer (NMIBC) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Adstiladrin<\/p>\n<\/li>\n

      2. \n

        Keytruda<\/p>\n<\/li>\n

      3. \n

        Vicinium<\/p>\n<\/li>\n

      4. \n

        N-803 (ALT-803) <\/p>\n<\/li>\n

      5. \n

        TLD-1433<\/p>\n<\/li>\n

      6. \n

        CG0070<\/p>\n<\/li>\n

      7. \n

        Padcev<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/non-muscle-invasive-bladder-cancer-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Non-muscle Invasive Bladder Cancer (NMIBC) Patient Share (%) Overview at a Glance<\/p>\n

        5. Non-muscle Invasive Bladder Cancer (NMIBC) Market Overview at a Glance<\/p>\n

        6. Non-muscle Invasive Bladder Cancer (NMIBC) Disease Background and Overview<\/p>\n

        7. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Non-muscle Invasive Bladder Cancer (NMIBC) <\/p>\n

        9. Non-muscle Invasive Bladder Cancer (NMIBC) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Non-muscle Invasive Bladder Cancer (NMIBC) Emerging Therapies<\/p>\n

        12. Non-muscle Invasive Bladder Cancer (NMIBC) Market Outlook<\/p>\n

        13. Country-Wise Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Non-muscle Invasive Bladder Cancer (NMIBC) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Non-muscle Invasive Bladder Cancer (NMIBC)-Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cNon-muscle Invasive Bladder Cancer (NMIBC)\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Non-muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-muscle Invasive Bladder Cancer (NMIBC) … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-546112","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=546112"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546112\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=546112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=546112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=546112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}